Concise Syntheses of $\Delta^{12}$-Prostaglandin J Natural Products via Stereoretentive Metathesis

Jiating Li,†‡ Tonia S. Ahmed,† Chen Xu,*,†‡‡ Brian M. Stoltz,*,†‡ and Robert H. Grubbs*†‡

*The Arnold and Mabel Beckman Laboratory of Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States
‡Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen, Guangdong 518000, China

Supporting Information

ABSTRACT: $\Delta^{12}$-Prostaglandin J family is recently discovered and has potent anticancer activity. Concise syntheses of four $\Delta^{12}$-prostaglandin J natural products (7–8 steps in the longest linear sequences) are reported, enabled by convergent stereoretentive cross-metathesis. Exceptional control of alkene geometry was achieved through stereoretention.

Prostaglandins are an important class of naturally occurring molecules that are found in mammalian tissues and exhibit a broad range of biological functions and widespread medical applications. Efforts directed toward the synthesis of various prostaglandins has had a profound effect on the development of new strategies and tactics employed in the field of synthetic chemistry, emanating from the seminal studies of Corey beginning in the 1960s. The recently discovered $\Delta^{12}$-prostaglandin J family (1–4, Scheme 1) features a unique cross-conjugated dienone motif and appealing anticancer activity. $\Delta^{12}$-PGJ$_3$ (3), for example, was isolated as a secondary metabolite and was shown to selectively induce apoptosis of leukemia stem cells over normal hematopoietic stems cells with high potency. Studies of its stability, bioavailability, and hypersensitivity make $\Delta^{12}$-PGJ$_3$ an intriguing drug candidate for leukemia treatment. Synthetic efforts toward $\Delta^{12}$-prostaglandin J compounds began in 2003, with a number of syntheses of $\Delta^{12}$-PGJ$_3$ (1) and 15d-PGJ$_2$ (2) reported through various approaches. Elegant contributions to the total synthesis of $\Delta^{12}$-PGJ$_3$ (3) were reported by Nicolaou and co-workers and more recently by the Aggarwal group. A number of $\Delta^{12}$-PGJ$_3$ analogues were also accessible via a streamlined synthesis developed by Nicolaou and co-workers to enable a comprehensive structural-activity relationship (SAR) study of their anticancer activities.

Olefins cross-metathesis is a convergent method for building C=C double bonds in natural product syntheses, however, it has seldom been applied in the previous syntheses of $\Delta^{12}$-PGJ family. Most importantly, conventional metathesis catalysts typically give imperfect control of alkene geometry. Previous syntheses relied on the semihydrogenation of alkynes or Wittig reactions, requiring multistep functional group manipulation with concomitant waste generation. From a strategic perspective, chemoselectivity among multiple alkenes has also been another concern, especially in the later stages. Stereoselective and alkene-chemoselective metathesis catalysts are in demand to realize a convergent synthesis from simple alkene building blocks.

A series of cyclometalated ruthenium-based catalysts (e.g., Ru-1, Ru-2, Figure 1) were recently developed by Grubbs and co-workers and enabled Z-selective metathesis through a favored syn-metallacyclobutane intermediate (Figure 1, Path A). More recently, catechodithiolate-based catalyst Ru-3 and its dithiolate variants were developed by Hoveyda group and showed high Z-selectivity in ring-opening metathesis polymerizations, ring-opening cross-metathesis, and cross-metathesis with ZZ-olefins. In fact, high kinetic E-selectivity in cross-metathesis with E-starting materials was also observed with Ru-3, the sIPr analogue Ru-4, and other less bulky fast-initiating analogues developed by Materia Inc. and the Grubbs group, which defined these catalysts as stereoretentive. The origin of the stereoretention was attributed to the formation of
a side-bound metallacyclobutane intermediate, of which the α-substituents are forced down to minimize steric interactions with the bulky N-aryl groups of the NHC. As a result, when starting with Z-alkenes, the β-substituent points down to generate Z-alkene products (Figure 1, Path B). When starting with E-alkenes, however, the β-substituent has to point up into the open space between two N-aryl groups, leading to the generation of E-alkene products, albeit with slower rates (Figure 1, Path C). Cross-metathesis between two terminal alkenes is not possible with stereoretentive metathesis catalysts, however, because the intermediate methylidene species are unstable and lead to catalyst decomposition.\(^\text{12d}\) A methylene capping strategy was recently reported as a remedy to this problem, enabling the cross-metathesis of two terminal alkenes.\(^\text{13}\)

Despite the unique properties of these stereoretentive catalysts, to date, limited synthetic evaluation of these catalysts has been conducted.\(^\text{15}\) Herein, we present a total synthesis of the olefin-enriched \(\Delta^{12}\)-prostaglandin J natural products 1\textasciitilde4 by implementing a concise stereoretentive metathesis approach. This also sets a perfect test ground to evaluate the reactivity, chemoselectivity, and functional group compatibility of these newly developed metathesis catalysts.

Retrosynthetically, \(\Delta^{12}\text{-PGJ}_3\) (3) for example can be simplified into a truncated prostaglandin structure 22 by use of stereoretentive metathesis (Scheme 1). A three-component coupling strategy could be applied toward the synthesis of 22, using a relatively simple and commercially available allyl Grignard reagent, \(\omega\)-chain aldehyde 21, and a chiral cyclooctatetraene (R)-6. The O-Boc group of (R)-6 can be used as a traceless stereoinductive group to set the C8 stereocenter.\(^\text{17}\)

We initially aimed to synthesize \(\Delta^{12}\text{-PGJ}_3\) (1). Chiral cyclooctatetraene (R)-6 was prepared from furfuryl alcohol in a three-step process including a kinetic resolution method developed by Reiser and co-workers (Scheme 2A).\(^\text{18}\) The \(\omega\)-chain aldehyde 10 was prepared from hexanal (7) through asymmetric Keck allylation,\(^\text{19}\) TBS protection, and ozonolysis (Scheme 2B). With all the starting materials for the three-component coupling in hand, CuBr-Me,S and LiCl facilitated the diastereoselective conjugate addition of the allyl magnesium bromide. The enolate formed can then be trapped by the subsequently added \(\omega\)-chain aldehyde electrophile, and the O-Boc group was eliminated in the course of the aldol reaction to form the desired cyclooctatetraene. Elimination with MsCl and DMAP favored 12E-product 11 as the major product in reasonable yield (45% over 2 steps, Scheme 2D).

Stereoretentive metathesis was then evaluated on 11. Because 11 cannot react with another terminal alkenes using stereoretentive metathesis catalysts, we considered a symmetric Z-alkene 13 as the coupling partner, which could also be made by homodimerization of readily available 12 through stereoretentive metathesis. With 1 mol % loading of Ru-4 as the catalyst, 98% conversion could be achieved by applying dynamic vacuum to remove the byproduct, cis-3-hexene (bp 66\text{-}68 °C) from the reaction mixture. Next, 11 with an additional 5 mol % catalyst Ru-4 were added into the reaction mixture, and the alcohol product 14 could be isolated in 95% yield in high Z-selectivity (>99% Z). This result established the efficacy of an efficient one-pot, stereoretentive homodimerization/cross-metathesis strategy to build the C5 Z-alkene. In contrast, synthesis of PGE\(_2\) and PGE\(_{2\alpha}\) required a large excess of gaseous butene and more complicated operations in the previously reported methylene capping strategy.\(^\text{14}\) Lye oxidation and deprotection of the TBS group of 14 in aqueous HF furnished the natural product \(\Delta^{12}\)-prostaglandin J\(_3\) (1) in 89% yield over the last two steps.

The same three-component coupling sequence was performed to obtain 16, and the enal functionality of aldehyde 15 was well tolerated in the aldol step. 16 was then subjected to the standard one-pot stereoretentive homodimerization/cross-metathesis conditions, and alcohol 17 was obtained in excellent yield (93% yield, Scheme 2D) with high Z-selectivity (>99% Z). The C14 E-alkene tolerated the reaction, consistent with the much slower reaction of E-alkenes with Ru-4 as seen previously.\(^\text{13}\) We also assessed the enantiopurity of intermediates 16 and 17. Three-component coupling product 16 proceeded with a small loss in enantiopurity (88% ee) from (R)-6 (>99% ee), but the metathesis product 17 was obtained without significant erosion of enantiopurity (87% ee). This result demonstrates that stereoretentive metathesis with catalyst Ru-4 also retained the stereochemistry of the C8 stereocenter. Lye oxidation of 17 again gave 15-deoxy-\(\Delta^{12}\)-prostaglandin J\(_3\) (2) in 68% yield.

Synthesis of \(\Delta^{12}\)-prostaglandin J\(_3\) (3) began with the preparation of the \(\omega\)-chain aldehyde 21. We envisioned the Z-alkene in 21 could also be generated from stereoretentive metathesis. First, we obtained chiral alcohol 18 through a reported chiral pool strategy with (R)-epichlorohydrin as the starting material (Scheme 2C).\(^\text{20}\) TBS protection of the alcohol and subsequent removal of the 1,3-dithiol gave aldehyde 20. Stereoretentive metathesis of 20 with an excess

---

**Figure 1.** Z-Selective and stereoretentive metathesis catalysts and models of their stereoselectivity.
amount of cis-3-hexene using catalyst Ru-4 (4 mol %) afforded ω-chain aldehyde 21 in good yield (88%) with high Z-selectivity (>99% Z). The short synthesis of aldehyde 21 proved that a broad range of functional groups, including aldehydes, can be tolerated without protecting group manipulations using stereoretentive catalysts. Then, 22 was synthesized through the standard three-component coupling sequence from (R)-6 (Scheme 2D). Surprisingly, fast ring-closing metathesis (RCM) with Ru-4 yielded 24 as a byproduct (31% yield) bearing an unusual 9-membered ring, and the desired alcohol product 23 was obtained in only 44% yield.

Alternatively, we chose to use cyclometalated catalyst Ru-2 to circumvent the crossover of alkene reactivity. Because trisubstituted metallacyclobutane intermediates are highly unfavorable with this cyclometalated catalyst, this pathway can be easily avoided (Scheme 2E).21 Chemoselective cross-metathesis of 5-hexen-1-ol (25) with the allyl group of 22 furnished the desired product 23 in good yield (52%) with a trace amount of byproduct 26 (less than 2%, Scheme 2F). The RCM product 24 was not observed under these conditions. The side-reaction of C17 internal Z-alkene could be attributed to ethylene produced or the residual ruthenium methylidene species in the solution. Then, Ley oxidation of 23 and
deprotection of the TBS group with aqueous HF provided $\Delta^{12}$-prostaglandin J$_3$ (3) in 8 linear steps.

Finally, in the synthesis of 15d-PGJ$_3$ (4), crossover of metathesis reactivity between the allyl group and the C17 Z-alkene of 28 could also be expected. Standard stereoretentive metathesis conditions with Ru-4 provided desired product 29 in 36% yield and byproducts 30 and 31 (Scheme 2F).$^{22}$ Compared to $\Delta^{12}$-PGJ$_3$ (3) synthesis, where the steric bulk of the OTBS group may be beneficial to achieving good chemoselectivity, 28 has no such steric hindrance. However, no RCM of 28 was observed, possibly due to the ring strain of RCM product. Though 30 could not be separated from 29, the mixture was subjected to PCC oxidation and Pinnick oxidation conditions,$^{23}$ allowing us to isolate 15-deoxy-$\Delta^{12,14}$-prostaglandin J$_3$ (4) (12% yield from 28).

In conclusion, we report a concise and convergent synthesis of four $\Delta^{12}$-prostaglandin J natural products in shorter sequences (7–8 steps in the longest linear sequences) empowered by stereoretentive and stereoselective metathesis. Furthermore, the reactivity, chemoselectivity, and functional group compatibility of stereoretentive metathesis were evaluated. This study should inspire further practical applications of stereoretentive metathesis, such as a facile one-pot stereoretentive homodimerization/cross-metathesis strategy to introduce Z-alkenes with excellent geometric control. The modularity and expediency of this chemistry open the synthesis of other prostaglandins and analogues to enable SAR studies in cancer treatment. With the well-defined kinetically Z/E-selective catalysts that have been developed to overcome the inherent thermodynamic preference of alkene product geometry, olefin metathesis can play a pivotal role in the synthesis design.

■ ASSOCIATED CONTENT

 Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.8b12816.

Characterization data, and experimental data (PDF)

■ AUTHOR INFORMATION

Corresponding Authors
*rhg@caltech.edu
stoltz@caltech.edu
*xuc@sustc.edu.cn

ORCID
Jianming Li: 0000-0001-6646-5693
Chen Xu: 0000-0002-3222-459X
Brian M. Stoltz: 0000-0001-9837-1528
Robert H. Grubbs: 0000-0002-0057-7817

Notes
The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We acknowledge funding from NIH (R01GM031332 and R01GM080269) and NSF CHE 150216. T.S.A. acknowledges NSF for support through a graduate research fellowship. Materia, Inc. is thanked for generous donations of catalysts. A. W. Sun, E. R. Welin, and Y. Xu are thanked for helpful discussion and input on this paper. Dr. Scott C. Virgil (Caltech) is thanked for assistance with chiral-SFC and HPLC separation. K. Chen from F. H. Arnold lab is thanked for his help with Biotage separation. Dr. David VanderVelde (Caltech) and Dr. Mona Shahgholi (Caltech) are acknowledged for help in structural determination and characterizations. This paper is dedicated to Professor E. J. Corey on the occasion of his 90th birthday.

■ REFERENCES


(22) As well as byproducts 29, 30 was obtained using Ru-2 and no improvement of chemoselectivity was observed (see Supporting Information).

(23) Ley oxidation of a mixture of 29 and 30 was also performed but resulted in a significant amount of decomposition products.